Jing Liu

Jing Liu

Auto-generated profile, based on publicly available information

Jing Liu

Department of Urology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
YGYang Gao
Yang Gao
NNNaoe Taira Nihira
Naoe Taira Nihira
XBXia Bu
Xia Bu
CCChen Chu
Chen Chu
JZJinfang Zhang
Jinfang Zhang
WWWenyi Wei
Wenyi Wei

21 February 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
JLJing Liu
Jing Liu
HCHe Chen
He Chen
LMLeina Ma
Leina Ma
ZHZhixiang He
Zhixiang He
DWDong Wang
Dong Wang
WWWenyi Wei
Wenyi Wei
Opto-PROTAC adds a light-inducible switch on PROTAC, enabling optical control for targeted degradation of proteins of interest .

30 June 2023 in Science
Verified
Journal Article
Closed access
TZTao Zhang
Tao Zhang
DXDaichao Xu
Daichao Xu
ETElijah Trefts
Elijah Trefts
MLMingming Lv
Mingming Lv
HIHiroyuki Inuzuka
Hiroyuki Inuzuka
WWWenyi Wei
Wenyi Wei
Adenosine monophosphate–activated protein kinase (AMPK) activity is stimulated to promote metabolic adaptation upon energy stress. However, sustained metabolic stress may cause cell death. The mechanisms by which AMPK dictates cell death are not fully understood. We report that metabolic stress promoted receptor-interacting protein kinase 1 (RIPK1) activation mediated by TRAIL receptors, whereas AMPK inhibited RIPK1 by phosphorylation at Ser 415 to suppress energy stress–induced cell death. Inhibiting pS415-RIPK1 by Ampk deficiency or RIPK1 S415A mutation promoted RIPK1 activation. Furthermore, genetic inactivation of RIPK1 protected against ischemic injury in myeloid Ampkα1 -deficient mice. Our studies reveal that AMPK phosphorylation of RIPK1 represents a crucial metabolic checkpoint, which dictates cell fate response to metabolic stress, and highlight a previously unappreciated role for the AMPK-RIPK1 axis in integrating metabolism, cell death, and inflammation.

15 July 2020 in Cell Research
Verified
Journal Article
Closed access
PDF file
JLJing Liu
Jing Liu
YPYunhua Peng
Yunhua Peng
LSLe Shi
Le Shi
Lixin WanLixin Wan
Lixin Wan
HIHiroyuki Inuzuka
Hiroyuki Inuzuka
WWWenyi Wei
Wenyi Wei

17 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJing Liu
Jing Liu
XBXia Bu
Xia Bu
CCChen Chu
Chen Chu
XDXiaoming Dai
Xiaoming Dai
JAJohn M. Asara
John M. Asara
WWWenyi Wei
Wenyi Wei
Activation of the cGAS/STING innate immunity pathway is essential and effective for anti-tumor immunotherapy. However, it remains largely elusive how tumor-intrinsic cGAS signaling is suppressed to facilitate tumorigenesis by escaping immune surveillance. Here, we report that the protein arginine methyltransferase, PRMT1, methylates cGAS at the conserved Arg133 residue, which prevents cGAS dimerization and suppresses the cGAS/STING signaling in cancer cells. Notably, genetic or pharmaceutical ablation of PRMT1 leads to activation of cGAS/STING-dependent DNA sensing signaling, and robustly elevates the transcription of type I and II interferon response genes. As such, PRMT1 inhibition elevates tumor-infiltrating lymphocytes in a cGAS-dependent manner, and promotes tumoral PD-L1 expression. Thus, combination therapy of PRMT1 inhibitor with anti-PD-1 antibody augments the anti-tumor therapeutic efficacy in vivo. Our study therefore defines the PRMT1/cGAS/PD-L1 regulatory axis as a critical factor in determining immune surveillance efficacy, which serves as a promising therapeutic target for boosting tumor immunity.

29 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJian Ma
Jian Ma
LLLei Li
Lei Li
BMBohan Ma
Bohan Ma
TLTianjie Liu
Tianjie Liu
ZWZixi Wang
Zixi Wang
WWWenyi Wei
Wenyi Wei
CDK4/6 inhibitors (CDK4/6i) show anticancer activity in certain human malignancies, such as breast cancer. However, their application to other tumor types and intrinsic resistance mechanisms are still unclear. Here, we demonstrate that MYC amplification confers resistance to CDK4/6i in bladder, prostate and breast cancer cells. Mechanistically, MYC binds to the promoter of the E3 ubiquitin ligase KLHL42 and enhances its transcription, leading to RB1 deficiency by inducing both phosphorylated and total pRB1 ubiquitination and degradation. We identify a compound that degrades MYC, A80.2HCl, which induces MYC degradation at nanomolar concentrations, restores pRB1 protein levels and re-establish sensitivity of MYC high-expressing cancer cells to CDK4/6i. The combination of CDK4/6i and A80.2HCl result in marked regression in tumor growth in vivo. Altogether, these results reveal the molecular mechanisms underlying MYC-induced resistance to CDK4/6i and suggest the utilization of the MYC degrading molecule A80.2HCl to potentiate the therapeutic efficacy of CDK4/6i.